Compare GLDD & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLDD | ABUS |
|---|---|---|
| Founded | 1890 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 929.6M |
| IPO Year | 2007 | 2008 |
| Metric | GLDD | ABUS |
|---|---|---|
| Price | $17.01 | $4.61 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $17.00 | $5.00 |
| AVG Volume (30 Days) | 1.8M | ★ 1.9M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 28.57 | ★ 55.26 |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $702,503,000.00 | $14,083,000.00 |
| Revenue This Year | $5.19 | N/A |
| Revenue Next Year | $7.56 | $783.24 |
| P/E Ratio | $15.74 | ★ N/A |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $8.49 | $3.04 |
| 52 Week High | $17.02 | $5.10 |
| Indicator | GLDD | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 68.41 | 55.64 |
| Support Level | $14.60 | $4.19 |
| Resistance Level | N/A | $4.64 |
| Average True Range (ATR) | 0.03 | 0.19 |
| MACD | -0.06 | 0.03 |
| Stochastic Oscillator | 80.00 | 76.61 |
Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The Company is also fully engaged in expanding its core business into the offshore energy industry. Dredging involves the enhancement or preservation of the navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand, or rock. Company work generally is to performed in coastal waterways and deep water ports. Its project portfolio includes Coastal Restoration, Coastal Protection, Ports and Harbors, International, and Inland Dredging.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.